Evaxion Announces Data From Its Phase 2 Study Of EVX- In Participants With Advanced Melanoma Demonstrates Induced Immune Responses, Underlines Predictive Performance
Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new biomarker data from its phase 2 trial with
Evaxion's cancer medicine showed it can trigger immune system responses. When you see this data, watch if doctors think it actually helps patients feel better.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.